Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Genfit stock (GNFT)

Buy Genfit stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Genfit is a biotechnology business based in the US. Genfit shares (GNFT) are listed on the NASDAQ and all prices are listed in US Dollars. Genfit employs 159 staff and has a trailing 12-month revenue of around $34.5 million.

Our top picks for where to buy Genfit stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Genfit stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – GNFT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Genfit stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 3.1 / 5: ★★★★★
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Genfit stock price (NASDAQ: GNFT)

Use our graph to track the performance of GNFT stocks over time.

Genfit shares at a glance

Information last updated 2024-07-22.
Latest market close$4.16
52-week range$2.89 - $6.05
50-day moving average $4.38
200-day moving average $3.73
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.63

Is it a good time to buy Genfit stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genfit price performance over time

Historical closes compared with the close of $4.16 from 2024-07-19

1 week (2024-07-16) -6.52%
1 month (2024-06-21) 7.22%
3 months (2024-04-23) 20.76%
6 months (2024-01-23) 6.94%
1 year (2023-07-21) 6.12%
2 years (2022-07-22) 0.24%
3 years (2021-07-23) 9.47%
5 years (2019-07-23) 17.87

Genfit financials

Revenue TTM $34.5 million
Gross profit TTM $26.2 million
Return on assets TTM -9.91%
Return on equity TTM -35.57%
Profit margin -83.79%
Book value $1.37
Market Capitalization $228.8 million

TTM: trailing 12 months

Genfit share dividends

We're not expecting Genfit to pay a dividend over the next 12 months.

Genfit share price volatility

Over the last 12 months, Genfit's shares have ranged in value from as little as $2.894 up to $6.05. A popular way to gauge a stock's volatility is its "beta".

GNFT.US volatility(beta: 1.07)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genfit's is 1.065. This would suggest that Genfit's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Genfit overview

Genfit S. A. , a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Frequently asked questions

What percentage of Genfit is owned by institutions?
Currently 0.205% of Genfit shares are held by institutions.
How many people work for Genfit?
Latest data suggests 159 work at Genfit.
When does the fiscal year end for Genfit?
Genfit's fiscal year ends in December.
Where is Genfit based?
Genfit's address is: Parc EurasantE, Loos, France, 59120
What is Genfit's ISIN number?
Genfit's international securities identification number is: US3722791098
What is Genfit's CUSIP number?
Genfit's Committee on Uniform Securities Identification Procedures number is: 372279109

More guides on Finder

Ask a question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site